ProKidney:Guggenheim upgrades to Buy, raises PT to $7 from $6.

ProKidney:Guggenheim upgrades to Buy, raises PT to $7 from $6.

Guggenheim has upgraded its rating on ProKidney Corp. (NASDAQ: PROK) to Buy and raised its price target to $7.00 from $6.00, according to a report released on July 2, 2025 [1]. The new target is within the broader analyst range of $1.00 to $9.00. This move comes after ProKidney's Phase 2 REGEN-007 trial demonstrated promising results, leading to a significant surge in the company's stock price.

The trial, which evaluated rilparencel, a potential treatment for chronic kidney disease (CKD) in patients with diabetes, showed statistically significant improvements in kidney function. Group 1 patients experienced a 78% improvement in the annual decline of estimated glomerular filtration rate (eGFR) after treatment [2]. This positive data has sparked investor interest, with ProKidney's stock price surging by 67.56% in pre-market trading on July 9, 2025 [3].

Guggenheim increased its probability of success for rilparencel to 55% from 40% after consulting with company management and leading nephrologists. The experts suggested that if validated in Phase 3 trials, rilparencel could potentially delay the need for dialysis by several years in patients with Stage 3b/4 CKD. They also noted the treatment's safety profile is comparable to that of a kidney biopsy [1].

Citi analysts also responded to the positive trial data by raising their price target for ProKidney to $9.00, increasing the probability of success for the treatment to 60%. However, BofA Securities maintained its Underperform rating on ProKidney, expressing concerns about trial risks and regulatory uncertainties [4].

ProKidney is expected to provide a regulatory update next month following its Type B Meeting with the FDA. The company is preparing to present the full REGEN-007 data at the American Society of Nephrology Meeting in November [1].

The positive trial results have sparked a surge in investor interest, with ProKidney's stock price experiencing a monumental increase. The company's shares have traded near their 52-week high, reflecting the market's optimism about the potential of rilparencel [3]. However, despite the promising data, ProKidney remains a high-risk investment, given the uncertainties associated with clinical trials and regulatory approvals.

References:
[1] https://www.investing.com/news/analyst-ratings/prokidney-stock-price-target-raised-to-7-from-6-at-guggenheim-93CH-4133854
[2] https://www.ainvest.com/news/prokidney-stock-soars-67-56-positive-trial-data-2507/
[3] https://www.gurufocus.com/news/2974590/guggenheim-raises-price-target-on-prokidney-prok-stock-prok-stock-news
[4] https://ng.investing.com/news/company-news/prokidney-reports-positive-results-from-rilparencel-ckd-trial-93CH-1997218